Nature’s Sunshine Products, Inc. (NASDAQ:NATR) Major Shareholder Sells $18,942.46 in Stock

Nature’s Sunshine Products, Inc. (NASDAQ:NATR) major shareholder Fosun Pharmaceutical Shanghai sold 1,399 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $13.54, for a total value of $18,942.46. Following the transaction, the insider now directly owns 75,963 shares in the company, valued at $1,028,539.02. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Fosun Pharmaceutical Shanghai also recently made the following trade(s):

• On Monday, October 14th, Fosun Pharmaceutical Shanghai sold 1,300 shares of Nature’s Sunshine Products stock. The shares were sold at an average price of $13.12, for a total value of $17,056.00.
• On Thursday, October 10th, Fosun Pharmaceutical Shanghai sold 3,000 shares of Nature’s Sunshine Products stock. The shares were sold at an average price of $13.39, for a total value of $40,170.00.
• On Tuesday, October 8th, Fosun Pharmaceutical Shanghai sold 1,800 shares of Nature’s Sunshine Products stock. The shares were sold at an average price of $13.13, for a total value of $23,634.00.

Nature’s Sunshine Products Price Performance

NASDAQ NATR opened at $13.32 on Thursday. The firm has a market cap of $249.48 million, a P/E ratio of 15.67 and a beta of 0.87. The stock’s 50-day moving average is $13.39 and its 200-day moving average is $15.48. Nature’s Sunshine Products, Inc. has a one year low of $10.81 and a one year high of $21.72.

Nature’s Sunshine Products (NASDAQ:NATR) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.18). The business had revenue of $110.55 million for the quarter. Nature’s Sunshine Products had a return on equity of 9.79% and a net margin of 3.50%.

Institutional Investors Weigh In On Nature’s Sunshine Products

A number of hedge funds have recently modified their holdings of the business. Paradigm Capital Management Inc. NY raised its position in shares of Nature’s Sunshine Products by 26.8% during the second quarter. Paradigm Capital Management Inc. NY now owns 695,079 shares of the company’s stock worth $10,475,000 after purchasing an additional 146,879 shares during the period. XTX Topco Ltd acquired a new stake in shares of Nature’s Sunshine Products during the second quarter worth about $180,000. Renaissance Technologies LLC raised its position in Nature’s Sunshine Products by 1.9% in the 2nd quarter. Renaissance Technologies LLC now owns 559,797 shares of the company’s stock valued at $8,436,000 after buying an additional 10,700 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Nature’s Sunshine Products by 4.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 786,966 shares of the company’s stock valued at $11,860,000 after buying an additional 34,996 shares during the last quarter. Finally, American Century Companies Inc. raised its position in Nature’s Sunshine Products by 25.7% in the 2nd quarter. American Century Companies Inc. now owns 260,479 shares of the company’s stock valued at $3,925,000 after buying an additional 53,221 shares during the last quarter. Institutional investors and hedge funds own 79.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Canaccord Genuity Group assumed coverage on Nature’s Sunshine Products in a research note on Friday, September 13th. They issued a “buy” rating and a $18.00 target price on the stock. Canaccord Genuity Group assumed coverage on Nature’s Sunshine Products in a research note on Friday, September 13th. They issued a “buy” rating and a $18.00 target price on the stock. StockNews.com raised Nature’s Sunshine Products from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 10th. Finally, DA Davidson cut their target price on Nature’s Sunshine Products from $23.00 to $21.00 and set a “buy” rating on the stock in a research note on Monday, August 12th.

About Nature’s Sunshine Products

Nature’s Sunshine Products, Inc, a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision.